Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Investing.com - Moderna (NASDAQ: MRNA) reported fourth quarter EPS of $-2.91, $0.18 worse than the analyst estimate of $-2.73. Revenue for the quarter came in at $966M versus the consensus estimate of $995.44M.
Guidance
Moderna sees FY 2025 revenue of $1.50M-$2.50M versus the analyst consensus of $2.22M.
Moderna's stock price closed at $31.92. It is down -19.21% in the last 3 months and down -64.98% in the last 12 months.
Moderna saw 4 positive EPS revisions and 6 negative EPS revisions in the last 90 days. See Moderna's stock price’s past reactions to earnings here.
According to InvestingPro, Moderna's Financial Health score is "fair performance".
Check out Moderna's recent earnings performance, and Moderna's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar